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Abstract 
The Beta-Carotene and Retinol Efficacy Trial tested the 
effect of the combination of/]-carotene (30 mg) and 
retinyl palmitate (25,000 units) daily on the incidence of 
lung cancer in high-risk individuals. In study centers 
located in Seattle, WA; Portland, OR; and Irvine, CA, we 
recruited current and recent ex-cigarette smokers, aged 
50-69 years. Our primary method of recruitment was by 
mailing study information and eligibility questionnaires to 
age-selected health insurance subscribers. A total of 
1,216,549 subscriber households were contacted, which 
resulted in 16,449 enrollments and 12,184 
randomizations. Other methods of recruitment yielded 
1421 enrollments and 1002 randomizations. Seventy-four 
% of those participants who enrolled in the 3-month 
placebo run-in were randomized. The major reasons for 
nonrandomization ce subjects were enrolled were: 
becoming ineligible (13%), concern about or development 
of side effects attributed to the study vitamins (18%), loss 
of interest or being too busy (23 %), and not showing up 
at the appointed time or not willing to come to the study 
center (23 %). Here, we discuss the reasons for 
nonparticipation and for subjects leaving the trial prior 
to randomization and possible modifications of trial 
design and procedures to address these problems. This 
recruitment approach provided a constant flow of 
potentially eligible participants, screened out many 
ineligible and uninterested persons prior to the 
scheduling of a study center visit, and ensured 
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randomization of committed participants. A major 
limitation of this study was that the pool of minorities 
that was reached was small. 
Introduction 
Large-scale human cancer prevention trials with the end point 
of cancer incidence are the gold standard for testing scientific 
and public health hypotheses ari ing from observational epide- 
miological, animal, and in vitro studies of dietary micronutri- 
ents, vitamins, and other potential chemoprevention agents. 
Recruitment to this type of disease prevention trial pre- 
sents a major challenge. In contrast o treatment trials in pa- 
tients diagnosed with cancer, primary prevention trials seek to 
enroll healthy participants who may not be receiving routine 
medical care and, therefore, cannot be recruited via the usual 
clinical trial methods of direct physician contact. In addition, 
primary prevention trials require long-term adherence to an 
intervention regimen to achieve adequate statistical power to 
detect a statistically significant reduction ( r increase) in inci- 
dence rates. Poor recruitment results or an unexpectedly high 
dropout rate can preclude successful completion of the trial. 
In 1985, we began recruitment toa cancer prevention trial 
in the largest clearly identifiable population at high risk for lung 
cancer, current and former heavy cigarette smokers. No cancer 
prevention trial in this population had previously been at- 
tempted in this country. 
Here, we present the methods used to recruit his popula- 
tion to the CARET, 3 the results and the reasons given by 
participants who left the trial prior to being randomized. Anal- 
yses of factors influencing retention rates over the follow-up 
periods exceeding 10 years will be reported separately. 
Materials and Methods 
From 1985 to 1988, we conducted two pilot trials to test the 
feasibility of a lung cancer primary prevention trial with /3- 
carotene and vitamin A in two healthy but high-risk popula- 
tions: current or former cigarette smokers (1) and individuals 
with a history of occupational sbestos exposure (2). Because 
of the marked differences in the recruitment methods for the 
two high-risk populations, we will only discuss recruitment of
the smoking population here. These pilot studies demonstrated 
successful recruitment, no toxicity, and high adherence to the 
regimen. In 1988, recruitment was expanded 10-fold to accrue 
sufficient participants o test the effect of the combination of 
these two agents on the incidence of lung cancer (3). The 
eligibility criteria for heavy smokers included: males and 
3 The abbreviations u ed are: CARET, Beta-Carotene and Retinol Efficacy Trial; 
HMO, health maintenance organization; AARP, American Association of Retired 
Persons; ATBC, Alpha-Tocopherol Beta-Carotene. 
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females, aged 50-69 years, with a smoking history of 20 
pack-years or greater, who were current smokers or recent 
ex-smokers (no more than 6 years since they had stopped). 
Participants were excluded if they had a history of cancer 
within 5 years or a diagnosis of cirrhosis. Active intervention 
was terminated in January 1996 after an interim analysis found 
evidence of no benefit and substantial evidence of harm (in- 
creased incidences of lung cancer and total mortality; Refs. 4 
and 5). 
Here, we focus on the 13,186 participants randomized at 
the three largest CARET study centers: the Fred Hutchinson 
Cancer Research Center in Seattle, Washington; the Kaiser 
Permanente Center for Health Research in Portland, Oregon; 
and the University of California Medical Center at Irvine, 
California. 
Direct Mail Recruitment. Our initial and predominant 
method of recruitment was by direct mailing of information to 
potential participants' homes. Regional health insurance carri- 
ers were our first sources of the mailing lists used. In most 
instances, the medical directors of these programs were con- 
tacted and given detailed information on the trial. After an 
internal discussion and general agreement, our proposed re- 
cruitment materials were reviewed and modified by the public 
relations and legal departments of each health care provider. 
The Washington State insurers who participated were: Blue 
Shield in King, Pierce, and Snohomish Counties (Western 
Washington); Blue Cross of Washington and Alaska; and two 
Washington HMOs, Group Health Cooperative of Puget Sound 
and Pacific Medical Center Cooperative. The insurance carriers 
participating in Oregon were Blue Cross/Blue Shield and three 
HMOs: Kaiser Permanente (Northwest Division), Capital 
Health Care, and Sisters of Providence/Good Health Plan. 
Those participating in southern California were Blue Cross/ 
Blue Shield and two HMOs: Kaiser Permanente (southern 
California Division) and Health Net. None of the insurers 
approached refused to participate. 
Each of the providers scanned its membership roles for 
subscribers in the eligible age range (50-69 years). This was 
the only cost-generating activity required of insurers. Recruit- 
ment packets were mailed by the study centers to the household 
address of each of these subscribers. An introductory letter was 
printed on the health care provider's tationery and signed by 
the company's medical director, explaining that participation i
the trial was an individual decision. This letter was mailed with 
the following: a one-page letter from the study investigators 
explaining the background, rationale, and outline of the trial; 
two one-page questionnaires to determine ligibility and poten- 
tial interest (for the subscriber and a potentially eligible house- 
mate); and a postpaid return envelope. To maintain confiden- 
tiality, two insurers required they conduct all processing and 
mailing of recruitment packets. 
In general, each study center mailed recruitment packets in 
weekly batches of 5,000-10,000. Returned questionnaires were 
reviewed to determine eligibility. The Portland Study Center 
sent a reminder postcard after 2 weeks and a second packet o 
households who did not return a questionnaire within 1 month. 
Most mailings were sent by first-class mail. To test relative 
costs and effectiveness, we sent some by first-class and some 
by bulk mail. These results are reported elsewhere (6). Each 
study center reviewed the returned interest urveys and 
screened out those who were ineligible because of age or lack 
of sufficient smoking history. Study centers telephoned all 
individuals who returned the screening questionnaire except 
those who were clearly ineligible. The purpose of the phone call 
was to review or clarify information on the interest survey, 
confirm eligibility, and schedule an appointment for the first 
study center visit. All activity through the first appointment is 
called recruitment. 
Other Recruitment Sources. We contacted the national of- 
rices of the AARP as a recruitment source. As an advocate for 
individuals over the age of 50, this national organization ap- 
peared to be ideal for recruiting healthy participants o preven- 
tion trials. Participation by AARP required review and approval 
of both the protocol and the consent form by the AARP scien- 
tific and executive boards, as well as by their legal advisers. 
CARET was the first trial to be given approval to recruit from 
regional AARP membership rolls. Recruitment methods were 
similar to that used with the health insurers, including a letter 
from a national officer of AARP. A limited number of mailings 
were sent to the AARP members in Washington and Oregon 
because approval from AARP was obtained close to the com- 
pletion of recruitment at these study centers. In contrast, the 
AARP mailing list was used more extensively at the Irvine 
Study Center. 
Seattle and Portland have large military bases in their 
surrounding communities. Associated with ese bases are large 
numbers of retired military personnel. We contacted the local 
retirement organizations of the Army, Air Force, Navy, and 
Coast Guard to recruit heir age-eligible retirees. All agreed to 
send a reformatted recruitment letter and packet. 
In both Washington and Oregon, the American Lung As- 
sociation has support groups for individuals with chronic lung 
diseases and/or those who wish to stop smoking (the "Lung 
Club" or "Better Breathers Club"). The American Lung Asso- 
ciation provided a mailing list so that these members could 
receive a recruitment packet. 
The Portland Study Center tested a pilot mailing to 6000 
random age-eligible individuals from a mailing list of registered 
motorists available from the State of Oregon and a list of 
"smokers/blue collar workers" purchased from Polk Direct 
Mail Advertising Company (Atlanta, GA). The latter list of 
smokers is available by zip codes and occupation categories. 
The Portland Study Center had access to two other local groups, 
smokers enrolled previously in a smoking cessation study 
within the Kaiser Permanente system and interested but ineli- 
gible respondents for the Oregon Health Sciences University 
Lung Health Study. The objective of both studies was to in- 
crease x-smoker rates. Neither study involved a pharmacolog- 
ical intervention agent. Both groups were sent CARET recruit- 
ment packets. 
Nondirected Mail Recruitment. In Washington, we at- 
tempted recruitment via Val-Pak, a commercial company that 
distributes tore coupons and general dvertising each month 
via the United States Postal Service. For marketing purposes, 
the Puget Sound region has been divided into geographic blocks 
of 10,000 households. For each of these blocks, demographic 
information (average income, age, sex, and ethnic composition) 
is available. We reformatted our recruitment letter and ques- 
tionnaire to a single page with a tear off return mailer and 
selected blocks with a high percentage of residents over age 50 
and a high percentage of ethnic minorities. Recruitment forms 
were distributed as part of the Val-Pak mailing in May 1992 
(20,000 households), July 1992 (20,000 households), and Sep- 
tember 1992 (40,000 households). 
In the Puget Sound region, the yearly home delivery of 
telephone books is accompanied by advertisement flyers and 
coupons. Our recruitment letter and mail-back form (formulat- 
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Table 1 Recruitment results using direct mail contact, by source" 
Eligible and interested 
No. of households Questionnaires No. returned per 
100 households contacted returned contacted No. % 
Enrolled Randomized participants 
No. % 
No. per 100 
No. households 
contacted 
Washington 
Blue Shield 
King County 79,689 8,799 11 3,511 40 1,659 47 1,257 1.6 
Pierce County 14,154 1,402 l0 777 55 418 54 326 2.3 
Snohomish County 11,243 1,394 12 595 43 208 35 156 1.4 
Blue Cross of Washington 49,668 3,030 6 868 29 649 75 484 1.0 
Group Health Cooperative-HMO 88,971 11,273 13 3,631 32 1,735 48 1,386 1.6 
Pacific Medical Center-HMO 21,937 1,497 7 766 51 403 53 327 1.5 
AARP 18,171 685 4 269 39 146 54 118 0.6 
Army retirees 27,941 2,842 10 982 35 409 42 322 1.2 
Air Force retirees 8,500 431 5 150 35 81 54 68 0.8 
Coast Guard retirees 1,210 135 11 46 34 21 46 11 0.9 
American Lung Association 1,800 100 6 32 32 16 50 7 0.4 
Subtotal/average 323,284 31,588 10 11,627 37 5,745 49 4,462 1.4 
Oregon 
Blue Cross/Blue Shield-Oregon 57,621 10,662 19 2,414 23 1,205 50 857 1.5 
Kaiser Permanente 88,966 24,756 28 5,176 21 3,088 60 2,205 2.5 
Capital HealthCare-HMO 10,732 2,112 20 347 16 108 31 82 0.8 
Group Health Plan-HMO 12,193 2,269 19 610 27 168 28 110 0.9 
AARP 27,499 1,399 5 461 33 208 45 146 0.5 
Military retirees 1,790 325 18 140 43 77 55 52 2.9 
American Lung Association 547 58 I1 16 28 13 81 6 1.1 
Stop Smoking Group 2,595 275 11 100 36 45 45 36 1.4 
Lung Health Research Study 2,662 387 15 192 50 84 44 62 2.3 
Smoker/blue collar 
workers mail list 48,059 2,883 6 589 20 280 48 196 0.4 
Department of motor vehicles 6,000 259 4 76 29 29 38 21 0.4 
Subtotal/average 258,664 45,385 18 10,121 22 5,305 52 3,773 1.5 
California 
Blue Cross/Blue Shield of California 76,823 8,680 11 2,452 28 917 37 684 0.9 
Kaiser Permanente 269,503 28,172 10 6,972 25 2,498 36 1,810 0.7 
Health Net-HMO 92,480 6,754 7 2,157 32 872 40 684 0.7 
AARP 195,795 6,637 3 2,356 35 1,112 47 771 0.4 
Subtotal/average 634,601 50,243 8 13,937 28 5,399 39 3,949 0.6 
Grand total/average 1,216,549 127,216 10 35,685 28 16,449 46 12,184 1.0 
ed for Val-Pak) was included with telephone books delivered to 
11,000 households in areas with high percentages of minorities. 
We tested the f asibility of using published advertising as 
a recruitment source with the Group Health Cooperative 
monthly magazine. This magazine is distributed to the 170,000 
Cooperative members (readership of 300,000) in the Puget 
Sound region. CARET purchased the back page for the months 
of December 1989 and March 1990, as our initial attempt a
recruitment from Group Health Cooperative. This full-page 
advertisement i cluded information about CARET and a "cut- 
out and mail-back" recruitment questionnaire. Separate adver- 
tised recruitment was attempted via a one-page insert that 
accompanied the grocery store advertising section of the 
weekly Seattle newspapers. We also placed informative posters 
about CARET with tear-off post cards in local pharmacies and 
physicians' offices. 
In Portland, we sent letters asking participants o "recruit 
a buddy." Posters with tear off postcards requesting information 
on CARET were placed in area pharmacies and physicians' 
offices. Recruitment was attempted through the outreach net- 
work of occupational health nurses in the African-American 
community, as well as through local church groups. 
Finally, in all study centers, participants were recruited via 
news media coverage in the form of articles in local newspa- 
pers, radio and television interviews, and, in Portland, paid 
newspaper and radio advertisements. 
Enrollment, Placebo Run-in, and Randomization. The en- 
rollment process for CARET began with the first study center 
visit. Baseline data were collected, eligibility was confirmed, 
and placebo capsules were dispensed to all participants. The 
enrollment phase continued until an individual was randomized 
(at the second visit), declined to participate before randomiza- 
tion, or was found to be ineligible. Three months (or up to a 
maximum of 6 months) after the enrollment visit, participants 
returned for a second visit, at which time study center staff 
re-reviewed eligibility. Eligible participants who had taken at 
least 50% of their study vitamins and were willing to continue 
in the study were then randomized. 
Results 
Recruitment by Source. Recruitment results based on the 
mailing of recruitment packets to individuals from various 
recruitment sources are presented in Table 1. CARET Study 
Centers contacted a total of 1,216,549 households via direct 
mail and from these households randomized 12,184 individu- 
als, resulting in a randomization rate of 1.0 per 100 households 
contacted by mail. The rates were higher in both Oregon (1.5/ 
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Table 2 Recruitment from other sources 
Estimated population reached No. responding No. eligible No. enrolled No. randomized 
Washington 
Nondirect mail or distribution 
Print media 
Seattle Scanner newspaper advertisement 
Seattle Chinese Post advertisement 
Seattle Post-InteUigencer a ticle 
Safeway advertisement 
View magazine (Group Health Cooperative) 
Radio news feature advertisement 
Television ews feature 
Other 
Oregon 
Community posters 
Department of Motor Vehicle mailing 
Print/radio news feature 
Other 
California 
Direct mail or distribution 
Print news feature 
Radio news feature 
Television news feature 
Other 
91,000 210 112 42 32 
20,000 0 0 0 0 
10,000 0 0 0 0 
207,299 2 2 
663,885 16 6 7 6 
300,000 251 134 89 64 
1 0 0 0 
53 18 0 0 
170 139 
6,000 
136 91 77 57 
128 60 35 24 
1,662 920 566 370 
54 33 
58 41 
176 132 
34 21 
36 27 
75 54 
100) and Washington (1.4/100) than in California (0.6/100). 
The highest recruitment yield from a major recruitment source 
was Kaiser Permanente in Portland (2.5 per 100 households 
contacted). We sent recruitment packets to 241,465 members of 
AARP; 8,721 individuals returned questionnaires (3.6 per 100 
households), of whom 1,035 (0.4 per 100 households) were 
randomized. 
Among all three study centers, we received 10.5 returned 
questionnaires per 100 households contacted. Of those who 
returned questionnaires, 35,685 (28%) appeared to be eligible 
and interested; of these, 16,449 (46%) had a first study center 
visit. Seventy-four % of those who had a first visit (12,184) 
were eventually randomized. 
Table 2 shows recruitment and enrollment rates for non- 
directed mail sources. Advertisement in the Group Health Co- 
operative subscriber magazine, which has a distribution of 
300,000 subscriber households, resulted in only 251 returned 
coupons; 134 of these were eligible (53%) and 64 were ran- 
domized (25%). Other sources of advertising recruitment (Ta-
ble 2) were less uccessful, yielding only eight randomized 
participants in Washington state. The Portland Study Center 
worked intensively with e print, radio, and television media 
when the trial started. In response to this publicity, 1662 inter- 
ested individuals telephoned the study center. A total of 370 
(22%) were randomized. The Irvine Study Center andomized 
132 participants who contacted the Center in response to print 
advertising. 
Enrollment and Randomization. Among the three study cen- 
ters, 9713 men and 8157 women came to the study center and 
completed a first visit. At that visit, 1726 dropped out and did 
not continue the enrollment process. After the ensuing 3-month 
placebo run-in period, an additional 2958 dropped out and were 
not randomized. The reasons for these dropouts are listed in 
Table 3. 
The most common reason for not being randomized was 
ineligibility. Of the 4684 participants who dropped out during 
the enrollment process, 946 were found to not fit the eligibility 
criteria at the first visit; an additional 388 were found to be 
ineligible by the time of the randomization visit. In addition, 
505 or 11% of participants decided not to participate in CARET 
explicitly because they wanted to take supplemental/3-carotene 
or more than 5500 units/day of supplemental vitamin A, mak- 
ing them ineligible. 
There were major differences in the reasons participants 
gave for leaving the study at the first visit compared to during 
or at the completion of the placebo run-in. At the first visit, 260 
individuals declined to join the study because of concerns about 
side effects highlighted in the informed consent, compared with 
107 who gave this as a reason for leaving the study after the 
run-in. At the conclusion of the placebo runqn, 403 (14%) left 
the study because of side effects that the participants attributed 
to/3-carotene and retinol. After joining the study, many partic- 
ipants appear to have decided that participation was too much 
of a time commitment. At the first visit, participants stated they 
were too busy 16 times, were not willing to come to the study 
center 35 times, and were not (or were no longer) interested 40 
times. At the second visit, hese figures increased to 331,301, 
and 350, respectively. 
Among the three study centers, there was little variation in 
the reasons why participants left the trial. Although not statis- 
tically significant, Irvine had fewer ineligible participants com- 
pared with Washington and Oregon; 21, 29, and 35% of non- 
randomized participants, respectively. In addition, the Irvine 
Study Center was actively recruiting at the time the ATBC trial 
published their results (7). This Finnish trial in high-risk smok- 
ers (a population similar to that recruited to CARET) reported 
that/3-carotene supplements were associated with an 18% in- 
creased incidence in lung cancer. We sent letters to each 
CARET participant just before publication of the ATBC results 
and reminded them of their right to withdraw. Over a 4-month 
time period, 74 of 5,777 enrolled (but not yet randomized) 
participants in the Califomia study center stopped taking 
CARET capsules, citing the results of the Finland trial as their 
reason. 
To determine whether there were differences in retention 
rates between recruitment sources, we evaluated the number of 
randomized participants actively taking the intervention agents 
at 24 and 48 months. There were no statistically significant 
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Table 3 Reasons for dropout at first visit to s udy center and after placebo run-in (second visit) 
Washington Oregon California Total 
First visit Second visit First visit Second visit First visit Second visit First visit Second visit 
Number of dropouts a 
Reason for dropout b 
Ineligible 286 (62%) 
Afraid of developing side effects 68 (15%) 
Concerned about monitored symptoms or signs that 0 (0%) 
have developed 
Concerned about nonmonitored symptoms or signs that 0 ( %) 
have developed 
Other health problems 31 (7%) 
Emotional problems but not grade 5 anxiety/depression c 15 (3%) 
Taking too many medications 4 (1%) 
Advised not to participate by p rsonal physician or study 0 (0%) 
center principal investigator 
Wanted to take/3-carotene or vitamin A over limit 64 (14%) 
Nonadherent to taking pills 2 (< 1%) 
Physical trouble taking pills 0 (0%) 
Did not like certain aspects of s udy 45 (10%) 
Not interested 7 (2%) 
No-show/out of window/unable to contact 1 (< 1%) 
Not willing or unable to come to study center 8 (2%) 
Had moved or was moving soon 3 (1%) 
Too busy 3 (1%) 
ATBC a results 0 (0%) 
Death 0 (0%) 
Other or no reason given 14 (3%) 
460 (34%) 890 (66%) 965 (54%) 815 (46%) 301 (19%) 1253 (81%) 1726 (37%) 2958 (63%) 
101 (11%) 519 (54%) 108 (13%) 141 (47%) 179 (14%) 946 (55%) 388 (13%) 
26 (3%) 154 (16%) 34 (4%) 38 (t3%) 47 (4%) 260 (15%) 107 (4%) 
56 (6%) 0 (0%) 62 (8%) 0 (0%) 52 (4%) 0 (0%) 170 (6%) 
72 (8%) 0 (0%) 75 (9%) 0 (0%) 86 (7%) 0 (0%) 233 (8%) 
94 (11%) 87 (9%) 81 (10%) 11 (4%) 101 (8%) 129 (7%) 276 (9%) 
23 (3%) 37 (4%) 18 (2%) 7 (2%) 26 (2%) 59 (3%) 67 (2%) 
8 (1%) 1 (<1%) 8 (1%) 1 (<1%) 9 (1%) 6 (<1%) 25 (1%) 
34 (4%) 8 (1%) 35 (4%) 3 (1%) 58 (5%) 11 (1%) 127 (4%) 
75 (8%) 143 (15%) 63 (8%) 49 (16%) 111 (9%) 256 (15%) 249 (8%) 
69 (8%) 11 (1%) 57 (7%) 2 (1%) 71 (6%) 15 (1%) 197 (7%) 
8 (1%) 4 (<1%) 4 (<1%) 2 (1%) 12 (1%) 6 (<1%) 24 (1%) 
73 (8%) 80 (8%) 48 (6%) 33 (11%) 83 (7%) 158 (9%) 204 (7%) 
126 (14%) 17 (2%) 87 (11%) 16 (5%) 137 (11%) 40 (2%) 350 (12%) 
78 (9%) 3 (<1%) 180 (22%) 0 (0%) 125 (10%) 4 (<1%) 383 (13%) 
146 (16%) 21 (2%) 78 (10%) 6 (2%) 77 (6%) 35 (2%) 301 (10%) 
34 (4%) 12 (1%) 21 (3%) 4 (1%) 43 (3%) 19 (1%) 98 (3%) 
159 (18%) 10 (1%) 72 (9%) 3 (1%) 100 (8%) 16 (1%) 331 (11%) 
0 (0%) 0 (0%) 0 (0%) 1 (<1%) 73 (6%) 1 (<1%) 73 (2%) 
9 (1%) 0 (0%) 8 (1%) 0 (0%) 8 (1%) 0 (0%) 25 (1%) 
43 (5%) 49 (5%) 36 (4%) 23 (8%) 103 (8%) 86 (5%) 182 (6%) 
a Percentages based on total number of nonrandomized individuals per study center. 
b Some participants gave more than one reason. Percentages were based on total number fn nra domized individuals per visit at each study center. Washington total does 
not include four participants who dropped out due to study center stopping randomization. California total does n  include 21 participants who dropped out due to Safety 
and Endpoint Monitoring Committee stopping randomization. 
c Symptom grading scale reported previously (1). 
a ATBC trial reported adverse effect of/3-carotene on lung cancer incidence in April 1994 (6). 
differences between sources, although the Portland Kaiser Per- 
manente population had the highest active rates at 88.5 and 
81.9% at 24 and 48 months, respectively, whereas the rates in 
the population who joined the trial as a result of advertisement 
(print, radio, or television) had the lowest rates, at 80.1 and 
76.7%, respectively. 
We determined the costs of recruitment via our direct mail 
approach. As reported previously, a total of $442 was spent for 
each randomized participant (8). Because 92% of all smoking 
participants were reached via direct mail, we did not compare 
the costs for the different methods of  recruitment. 
Table 4 shows the characteristics of the 7426 male and 
5760 female CARET participants randomized. The average age 
was 58 years. Ninety-four % were of European background, 
and 2% (217) had African heritage. Sixty-six % were current 
smokers, with a mean of  48 pack-years. Thirty-four % were 
ex-smokers with a smooth distribution of years since quit of  
1-6  years. The ex-smokers had a mean smoking history of 52 
pack-years. 
Discuss ion 
We were successful in the recruitment and randomization of a 
specific high-risk population (smokers and ex-smokers) 
through a direct mail strategy. The Physicians' Health Study (9) 
and The Women's  Health Study (10) used a similar recruitment 
strategy by mailing recruitment letters to health care profes- 
sionals. The prostate cancer prevention trial (11) and the breast 
cancer prevention trial (12, 13), conducted by the Southwest 
Oncology Group and the National Surgical Adjuvant Breast 
Project, respectively, recruited through their group members 
and their outreach programs, the Community Clinical Oncology 
Programs. These trials were also successful in recruiting and 
randomizing their projected accrual goals. Here, we provide the 
detailed results of our recruitment efforts, including the reasons 
participants gave when they chose not to join CARET. Our 
results, along with those of  the other major trials, should allow 
others to better plan recruitment strategies for large-scale pre- 
vention trials. 
There were differences in the rates of participants enrolled 
and randomized among recruitment sources and settings. Blue 
Cross/Blue Shield and their affiliates in Washington, Oregon, 
and California had rates of randomization of 1.6, 1.5, and 0.9 
persons per 100 households contacted, respectively. The lower 
rate in California may reflect demographics that were specific 
to the health insurance population enrolled in California or 
temporal changes because the mailings in California took place 
in 1992-1994, an average of 3 years later than in Washington 
and Oregon. There was much more resistance to randomization 
to a placebo-controlled trial, presumably because of  increased 
publicity and promotion of/3-carotene during that interval. 
Recruitment from HMOs did not appear to be better than 
from the general health-insured population. In Washington, the 
two participating HMOs randomized 1.6 and 1.5 persons per 
100 households. However, Kaiser Permanente in Oregon ran- 
domized 2.5 per 100 households contacted. Recruitment rates 
in the California HMOs were much lower (0.7). It is likely that 
the higher recruitment rate in Oregon reflects the status of  the 
Portland Study Center. The Center for Health Research in 
which the study center is located is organizationally and phys- 
ically part of Kaiser Permanente and has a long tradition of 
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Table 4 Randomized participant characteristics 
Washington Oregon California Total 
Mean age (SD) 
Male 
Female 
Ethnic origin 
European 
African 
Hispanic 
Asian 
Native American 
Other/no response 
No. of current smokers 
Mean pack-years (SD) 
Number of ex-smokers 
Years since quitting a 
<1 
1 
2 
3 
4 
5 
6 
>6 
Mean pack-years (SD) 
58 (6) 58 (5) 58 (6) 58 (6) 
57 (6) 58 (5) 58 (5) 58 (5) 
4,488 (95%) 4,144 (97%) 3,816 (90%) 12,446 (94%) 
63 (1%) 31 (1%) 123 (3%) 217 (2%) 
25 (1%) 23 (1%) 146 (3%) 193 (1%) 
68 (1%) 21 (<1%) 77 (2%) 166 (1%) 
42 (1%) 32 (1%) 27 (1%) 101 (1%) 
19 (<1%) 6 (<1%) 35 (1%) 63 (<1%) 
3,071 (65%) 2,936 (69%) 2,707 (64%) 8,714 (66%) 
48 (19) 48 (19) 50 (20) 48 (19) 
1,634 (35%) 1,321 (31%) 1,517 (36%) 4,472 (34%) 
127 (8%) 152 (12%) 160 (11%) 439 (10%) 
298 (18%) 214 (16%) 251 (17%) 763 (17%) 
247 (15%) 230 (17%) 242 (16%) 719 (16%) 
250 (15%) 224 (17%) 235 (16%) 709 (16%) 
236 (14%) 183 (14%) 214 (14%) 633 (14%) 
279 (17%) 227 (17%) 241 (16%) 747 (17%) 
192 (12%) 90 (7%) 173 (11%) 455 (10%) 
5 (<1%) 1 (<1%) 1 (<1%) 7 (<1%) 
52 (23) 51 (21) 53 (24) 52 (23) 
a Percentages based on number of ex-smokers. 
conducting health research among its members. Group Health 
Cooperative in Seattle maintains a similarly close research 
affiliation with its members. There is no doubt that the rela- 
tionship between the recruiting organization and individual 
participants i important. Rather than receiving a letter from an 
insurance company or an institution with which they have no 
affiliation, participants may view a letter from their HMO as a 
credible incentive for improved health. Such experience may 
encourage the growing managed care sector to organize and 
cooperate with academic partners in prevention trials. 
Recruitment from AARP was, in general, lower than that 
from other sources. In Washington and Oregon, the list pro- 
vided by AARP was the last source used. It is certain that many 
AARP members had already been contacted through our other 
sources, and those interested in joining the trial had, presum- 
ably, been enrolled. Hence, recruitment in these states may 
underestimate the true utility of this source. However, in Cal- 
ifornia, AARP was used for direct mail recruitment before other 
sources had been exhausted. From 195,795 packets mailed, the 
response rate was 3 persons per 100 households contacted, the 
lowest response rate seen from any source, and only 771 indi- 
viduals were randomized (0.4%). Although recruitment rates in 
southern California via all sources were lower than those in 
Oregon and Washington, we have no reason to believe that 
AARP recruitment in the latter states would have been signif- 
icantly better than the similar mailing to age-selected health 
insurance subscribers. 
There were multiple attempts to recruit participants via 
printed advertising. The results of these efforts were poor, 
although it is our impression that concurrent advertising 
increased the rate of response to mailings, particularly sec- 
ond mailings. Radio and television news appearances were 
more successful. These efforts resulted in a small number of 
participants calling the study center, but among those, a high 
percentage were eligible and were eventually randomized. It
is difficult to determine recruitment rates from these sources 
because the number of individuals contacted is unknown. 
Twenty-six % of all participants (29% of female and 24% 
of male participants) who had a first visit to the study center 
were not randomized. We attempted to categorize reasons par- 
ticipants gave for leaving the study at the time of enrollment 
and during the placebo run-in because some of these reasons 
may be addressed by changes in study procedures or operations 
(Table 5). This approach as limitations, however, because the 
purpose of a placebo run-in is to identify participants who are 
unlikely to be adherent for the full duration of the trial and 
avoid their randomization. 
Three hundred sixty-seven individuals were not ran- 
domized because they stated, at the first or second visit, that 
they feared side effects described in the consent form. An 
additional 403 participants left because of monitored or 
unmonitored symptoms or signs that developed uring the 
placebo run-in that the participant attributed to the study 
vitamins (Table 5). Although it is essential to inform par- 
ticipants of the potential side effects of the agents being 
tested, a clearer discussion f the incidence and severity of 
potential side effects and symptoms may be useful. For 
example, participants were concerned and requested addi- 
tional information about our warning for potential synergis- 
tic toxicity between vitamin A and alcohol. When we sub- 
sequently updated the consent form, we summarized results 
from the CARET pilot studies (1, 2), which showed no 
adverse interaction on liver function tests. 
One hundred thirty-eight participants were not randomized 
because they stated they were advised by their personal physi- 
cian not o participate in the study. However, on most occasions 
when personal physicians were contacted to discuss the trial, 
they expressed no concern about their patient's participation. 
Thus, the study interviewers felt that his explanation was often 
given by participants who did not want to continue in the trial. 
This loss might be reduced and subsequent retention be en- 
hanced if, prior to recruitment, local physicians are notified of 
the rationale for the trial and the expected low incidence of side 
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Table 5 Reasons for nonrandomization 
Washington Oregon California Total 
Enrolled 6,055 6,037 5,777 17,870 
Male 3,341 3,224 3,147 9,713 
Female 2,714 2,813 2,630 8,157 
No. of ineligibles/dropouts 1,350 (22%) 1,780 (30%) 1,554 (27%) 4,684 
Male 666 856 765 2,287 
Female 684 924 789 2,397 
Age of dropouts (yr), mean (SD) 57 (5) 58 (5) 58 (6) 58 (5) 
Reason for dropout a 
Ineligible 387 (29%) 627 (35%) 320 (21%) 1,334 (28%) 
Afraid of developing side effects 94 (7%) 188 (11%) 85 (5%) 367 (8%) 
Concerned about monitored symptoms or signs that have developed 56 (4%) 62 (3%) 52 (3%) 170 (4%) 
Concerned about nonmonitored symptoms or signs that have developed 72 (5%) 75 (4%) 86 (6%) 233 (5%) 
Other health problems 125 (9%) 168 (9%) 112 (7%) 405 (9%) 
Emotional problems but not grade 5 anxiety/depression 38 (3%) 55 (3%) 33 (2%) 126 (3%) 
Taking too many medications 12 (1%) 9 (<1%) 10 (1%) 31 (1%) 
Advised not to participate by personal physician or study center 34 (3%) 43 (2%) 61 (4%) 138 (3%) 
principal investigator 
Wanted to take/8-carotene or vitamin A over limit 139 (10%) 206 (12%) 160 (10%) 505 (11%) 
Nonadherent totaking pills 71 (5%) 68 (4%) 73 (5%) 212 (5%) 
Physical trouble taking pills 8 (1%) 8 (<1%) 14 (1%) 30 (1%) 
Did not like certain aspects of study 118 (9%) 128 (7%) 116 (7%) 362 (8%) 
Not interested 133 (10%) 104 (6%) 153 (10%) 390 (8%) 
No-show/out of window/unable to contact 79 (6%) 183 (10%) 125 (8%) 387 (8%) 
Not willing or unable to come to study center 154 (11%) 99 (6%) 83 (5%) 336 (7%) 
Had moved or was moving soon 37 (3%) 33 (2%) 47 (3%) 117 (2%) 
Too busy 162 (12%) 82 (5%) 103 (7%) 347 (7%) 
ATBC results 0 (0%) 0 (0%) 74 (5%) 74 (2%) 
Death 9 (1%) 8 (<1%) 8 (1%) 25 (1%) 
Other or no reason given 57 (4%) 85 (5%) 126 (8%) 268 (6%) 
a Some participants gave more than one reason. Percentages were based on total number of nonrandomized individuals per study center. Washington total does not include 
four participants who dropped out due to study center stopping randomization. California total does not include 21 participants who dropped out due to Safety and Endpoint 
Monitoring Committee stopping randomization. 
effects. Physician support may buttress a participant's lagging 
interest. 
Seven hundred twenty-three participants said they were 
unable to travel to the study center, did not show up at all, could 
not schedule a randomization visit within 6 months of the first 
visit, or were unable to be recontacted. This category of reason 
for dropping out appeared to be different between sites. The 
Seattle Study Center location in downtown Seattle had the 
highest percentage ofparticipants who were unwilling to come 
to the study center. Providing a study center that is easy to 
travel to and has adequate parking would help. 
Conclusions. Direct mail was an efficient method for recruit- 
ing high-risk smokers. We were able to contact a large number 
of individuals who would have been inaccessible via the usual 
methods of patient recruitment toclinical trials via physicians. 
The mail-in recruitment allowed successful screening of eligi- 
ble individuals and self-screening because onlythose interested 
and motivated responded and entered the recruitment enroll- 
ment process. The 3-month placebo run-in also helped assure 
high retention in CARET; 89% of alive participants were still 
active after a mean of 4 years of follow-up, despite the release 
of the adverse findings from the ATBC trial. 
This method can be exported readily to other sites in the 
United States and can be used by other trials using age as a 
primary eligibility criterion. With the cooperation of health 
insurers, this method can also provide a continuing source of 
age-eligible individuals because there is a constant flow of new 
individuals who join health plans, as well as individuals who 
age into the trial's age range criteria. 
Because this method was based on health insurance sub- 
scribers, it was less successful in recruiting economically dis- 
advantaged individuals, who are underrepresented among indi- 
viduals with health insurance. This has also been a challenge in 
recruitment efforts of other prevention trials. Recruitment by 
direct mail of these populations would require mailing lists 
aimed at these specific populations, as well as more intensive 
community-based r cruitment (14). 
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